Comparative Pharmacology
Head-to-head clinical analysis: DIABETA versus GLYNASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIABETA versus GLYNASE.
DIABETA vs GLYNASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glyburide is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to cell depolarization and calcium influx.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
Initial: 2.5-5 mg orally once daily, titrating to max 20 mg/day in 1-2 divided doses. Maintenance: 5-10 mg/day.
Initial dose 2.5-5 mg orally once daily with breakfast. Titrate by 2.5-5 mg weekly. Maximum dose 20 mg daily. Divided doses twice daily may be used for doses >10 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 10–12 hours in healthy individuals. Clinically, this supports once-daily dosing; may be prolonged in renal impairment.
Terminal elimination half-life: 10-16 hours; clinical context: correlates with duration of glucose-lowering effect, prolonged in renal impairment.
Approximately 50% renal (unchanged drug and metabolites), 50% biliary/fecal. Renal elimination accounts for 50% of dose, with about 20% unchanged and 30% as metabolites. Biliary excretion of metabolites contributes to fecal elimination.
Renal: approximately 50% as metabolites and unchanged drug; fecal/biliary: minor (less than 5% as unchanged drug).
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic